Last reviewed · How we verify

NCT04533841

Propranolol and Misoprostol Versus Misoprostol Alone for Induction of Labor in Primigravidas

Completed Phase 2 Last updated 31 August 2022
What this trial tests

Phase 2 trial testing Misoprostol in Induction of Labor Affected Fetus / Newborn in 128 participants. Completed in 15 September 2020.

Timeline
1 February 2020
Primary endpoint
13 September 2020
15 September 2020

Quick facts

Lead sponsorAhmed mohamed fathy ismail
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment128
Start date1 February 2020
Primary completion13 September 2020
Estimated completion15 September 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ahmed mohamed fathy ismail

Who can join

Adults 18 to 45, female only, with Induction of Labor Affected Fetus / Newborn. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare propranolol and misoprostol versus misoprostol alone for induction of labour in primigravidas

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A pilot study to compare propranolol and misoprostol versus misoprostol and placebo for induction of labor in primigravidae; a randomized, single-blinded, placebo-controlled trial.
    Abdel Hamid AS, Abdel Hamid AS, El Zeneiny H, Fathy A, et al · · 2023 · cited 3× · PMID 37016326 · DOI 10.1186/s12884-023-05537-1

Verify or expand the search:

Other trials of Misoprostol

Trials testing the same drug.

Other recruiting trials for Induction of Labor Affected Fetus / Newborn

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04533841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing